Stormer, I cant really argue with you.
It is a failed biotech and now a shell.
Some of these failed biotechs do have a molecule or pipeline products with further development potential and in a company with enough cash it can be developed further. Obviously you need someone who knows what they are looking at. In our current situation its a long shot and although a positive trial would have invited tens of millions of dollars to "get a look", perhaps a JV for a tenth of that price would still see a significant appreciation from here.
I understand exactly what you are saying though.
FTT Price at posting:
0.2¢ Sentiment: None Disclosure: Held
